Immunologic and imaging signatures in post tuberculosis lung disease

Area of Science:

• Immunology
• Pulmonology
• Pathology

Background:

• Post Tuberculosis Lung Disease (PTLD) is a significant global health issue affecting tuberculosis survivors.
• The underlying immune mechanisms driving PTLD are complex and not fully understood.
• Existing research has historically underinvestigated the immunological drivers of PTLD.

Purpose of the Study:

• To elucidate the immune-mediated paradigms contributing to human PTLD.
• To review the role of fibrotic granulomas and post-primary tuberculosis in PTLD development.
• To discuss novel host-directed therapies and imaging techniques for PTLD management.

Main Methods:

• Review of immune mechanisms, including T-helper-2 and T-regulatory cells, and TGF-β signaling in fibrotic granulomas.
• Analysis of the interplay between immune cells, cytokines, and proteases in post-primary tuberculosis-associated lung damage.
• Evaluation of repurposed medications (statins, metformin, doxycycline) as potential host-directed therapies (HDT).
• Assessment of novel imaging techniques, such as computed tomography, for PTLD phenotyping.

Main Results:

• Two immune-mediated paradigms are proposed to drive PTLD: fibrotic granulomas and post-primary tuberculosis sequelae.
• PTLD pathogenesis involves a complex balance of immune cells, cytokines, and host proteases perpetuating lung damage.
• Repurposed drugs and advanced imaging offer potential avenues for PTLD management and research.
• Current lack of biomarkers and trials hinders evidence-based PTLD treatment recommendations.

Conclusions:

• An integrated antifibrotic strategy targeting inflammatory and pro-fibrotic pathways is likely crucial for effective PTLD treatment.
• A combination of immunologic and radiographic markers may serve as successful surrogates for developing future HDTs.
• Further research is needed to establish evidence-based guidelines for PTLD management.